CIK 0001157601 · Large accelerated filer
MADRIGAL PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- MDGL
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- (267) 824-2827
- Business address
- 1001 CONSHOHOCKEN STATE ROAD, SUITE 2-350, WEST CONSHOHOCKEN, PA
- Former names
- MADRIGAL PHARMACEUTICALS, INC., SYNTA PHARMACEUTICALS CORP
- Open-market buys, last 90 days
- $35,023,032
- in 1 filing
- Open-market sales, last 90 days
- $7,011,938
- in 3 filings, $6.7M under 10b5-1 plans
Net +$28,011,094. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-03-03 | Huntsman Carole Chief Commercial Officer | Sale 10b5-1 | −100 | $326.34 | $33K | 9,367 |
| 2025-03-03 | Huntsman Carole Chief Commercial Officer | Sale 10b5-1 | −100 | $327.49 | $33K | 9,267 |
| 2025-03-03 | Huntsman Carole Chief Commercial Officer | Sale 10b5-1 | −100 | $329.64 | $33K | 9,167 |
| 2025-03-03 | Huntsman Carole Chief Commercial Officer | Sale 10b5-1 | −563 | $335.00 | $189K | 8,604 |
| 2025-02-28 | Waltermire Robert E. Senior VP, Chief Pharma Dev. | Sale | −1,052 | $340.99 | $359K | 3,903 |
| 2025-02-28 | Waltermire Robert E. Senior VP, Chief Pharma Dev. | Sale | −175 | $341.55 | $60K | 3,728 |
| 2025-02-27 | Sibold William John President and CEO | Option exercise | +50,000 | 104,303 | ||
| 2025-02-27 | Sibold William John President and CEO | Option exercise · Performance Restricted Stock Units | −50,000 | 0 | ||
| 2025-02-27 | Daly James M Director | Option exercise | +9,470 | $65.06 | $616K | 11,382 |
| 2025-02-27 | Daly James M Director | Option exercise | +6,000 | $111.06 | $666K | 17,382 |
| 2025-02-27 | Daly James M Director | Sale | −398 | $346.90 | $138K | 16,984 |
| 2025-02-27 | Daly James M Director | Sale | −14,302 | $347.39 | $5.0M | 2,682 |
| 2025-02-27 | Daly James M Director | Sale | −770 | $348.94 | $269K | 1,912 |
| 2025-02-27 | Daly James M Director | Option exercise · Stock Option (Right to Buy) | −9,470 | 0 | ||
| 2025-02-27 | Daly James M Director | Option exercise · Stock Option (Right to Buy) | −6,000 | 0 | ||
| 2025-02-27 | BATE KENNETH Director | Option exercise | +6,000 | $111.06 | $666K | 7,912 |
| 2025-02-27 | BATE KENNETH Director | Option exercise | +9,470 | $65.06 | $616K | 17,382 |
| 2025-02-27 | BATE KENNETH Director | Option exercise | +4,530 | $9.45 | $43K | 21,912 |
| 2025-02-27 | BATE KENNETH Director | Sale | −100 | $351.01 | $35K | 21,812 |
| 2025-02-27 | BATE KENNETH Director | Sale | −500 | $351.99 | $176K | 21,312 |
Page 26 of 82 · 1,629 trades